Ramucirumab, a fully human monoclonal antibody, specifically binds to VEGFR2 with high affinity, thus blocking the binding of VEGFR2 ligands which include VEGF-A, VEGF-C, and VEGF-D and contributing to the inhibition of VEGFR2-mediated tumor angiogenesis (Table 1) [39, 40]. Here, KDR is linked to neoplasm.